Lv3
330 积分 2024-12-12 加入
Locally advanced microsatellite instability-high esophagogastric cancer: are we ready to change our treatment paradigm?
24天前
已完结
Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?
24天前
已完结
Zolbetuximab: First Approval
1个月前
已完结
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
1个月前
已完结
Emerging targets in gastric and pancreatic cancer: Focus on Claudin 18.2
1个月前
已完结
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
1个月前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
1个月前
已完结
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
1个月前
已完结
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial
1个月前
已完结
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
1个月前
已完结
皖公网安备34019202002308
